Group items tagged

At last Friday's Clinical Congress Conference, the NHSE Chief Pharmaceutical Officer for England at NHS England, David Webb, announced the upcoming launch of the Pharmacy Stakeholder Forum- an initiative led by NHS England aimed to improve pharmacy professional leadership and foster collaboration within the sector. Webb highlighted the forum's significance as a platform for driving transformative change in pharmacy leadership. "The aim is to deliver collaboration to develop a stronger and more united voice for pharmacy professionals," Webb emphasised. Highlighting the need to drive transformative change in pharmacy leadership, he underscored that "the overarching goal is to address key challenges facing the pharmacy profession and chart a course for future development and innovation." Scheduled to commence in June, the Pharmacy Stakeholder Forum will provide a space for diverse organisations and networks with a vested interest in pharmacy professional leadership to converge.

Pharmacy leaders from across the sector need to work together in order to have a stronger voice in the future of the healthcare system, Sir Hugh Taylor, chair of the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB), has told Pharmacy Business. The establishment of this board in April 2024 was the principal recommendation of the UK Commission on Pharmacy Professional Leadership's report, published in February 2023. The report outlined that there is "an urgent need for the pharmacy professions to work collaboratively to deliver on their potential and, together, address a wide range of professional issues". "There's always been a measure of collaboration. And indeed, as we've begun our work, we've begun to unearth more examples of it, which is encouraging. But I think the conclusion that the UK Commission drew was that the fragmented nature of the professional leadership in pharmacy required something more concerted and organised in the form of the board," said Sir Hugh. Setup by the four UK chief pharmaceutical officers, the UKPPLAB is an independent public body, with the aim to enable greater collaboration across the pharmacy professional leadership bodies (PLBs) and specialist professional groups (SPGs), which are its constituent members.

Maxine McCabe has made history as the first community pharmacist in the UK to be credentialed as a core advanced pharmacist by the Royal Pharmaceutical Society (RPS) in Scotland. Announcing McCabe's achieving, NHS Education for Scotland (NES) stated that this credential demonstrates her expertise across the four pillars of advanced practice: clinical, leadership and management, educating others and research. Maxine has worked in the community pharmacy sector since qualifying as a pharmacist in 2008, consistently showing a keen interest in developing the wider pharmacy team and enhancing clinical services for the local patient population. Throughout her career, she has managed various community pharmacies, including Boots and Parkhead Health Centre Pharmacy, where she played a crucial role in developing pharmacy practice and nurturing pharmacy support roles and trainee pharmacists. In 2023, Maxine took on a part-time role as a Senior Educator in the Prescribing & Clinical Skills teams at NHS Education for Scotland (NES). She continues to practice as a pharmacist, leading the Teach and Treat Training Hub at Burnside Pharmacy in Lanarkshire. McCabe expressed her excitement about the recognition, saying, "I am delighted to obtain my Advanced Practice credential and showcase that this is achievable in community pharmacy."

Former superintendent pharmacist and National Pharmacy Association (NPA) director, Phil Galt, has been appointed the new UK managing director for pharmacy software supplier Cegedim Rx. The position was previously held by Adam Dennett, who resigned after a successful ten-year tenure to pursue a new career outside healthcare, the company said. Cegedim Rx, the pharmacy entity of Cegedim Healthcare Solutions UK, announced the new appointment this month (April 5). Tristan de Foucher, head of European operations for Cegedim Group, said: "Adam has been a force of nature in this business for the past 10 years. Under his leadership, the team has continuously and successfully invested in and driven product innovation to stay ahead of the ever-changing demands placed upon community pharmacy." Galt has over 20 years of experience as a qualified pharmacist and a successful business leader. He has worked extensively in community pharmacy, focusing on both care delivery and technology implementation.

Alitam Group, the 100-plus pharmacy store consolidation, has appointed Bharti Patel, the former group executive director of Avicenna to its executive board. Patel, who was part of the leadership team at Avicenna until late 2021, brings with her a wealth of experience covering pharmaceuticals, multiple retail and independent pharmacy, homecare and NHS primary and secondary care. In her early career, she worked at Lloyds Pharmacy, where she rose from a prescription medicines buyer to director of procurement over a period of eight years. She is known in the industry for her strong leadership, commercial acumen and ability to create opportunities for innovation and strategic partnerships. Alitam founder and CEO Feisal Nahaboo said in a statement that Patel's appointment will further strengthen the group's ability to deliver its transformative multi-billion-pound 'Pharmacy of the Future' concept.

Pharmacy hub and spoke specialists, Centred Solutions, has further strengthened its team with a key new appointment as the company expands its business. Ashley Kilgas, formerly sales director at Alliance Healthcare, has joined the company's executive team as chief commercial officer. An expert in sales leadership and customer relations with vast experience working in the healthcare and pharmacy sector, Kilgas will be tasked with building a high-performing commercial team to drive value for customers. Having worked closely with Centred Solutions on previous projects, Ashley already has an in-depth knowledge of the business. Expressing his excitement about his new role, Ashley said: "Centred Solutions is a pharmacy technology and automation company, with a tremendous amount of opportunity in front of it. There is currently nobody in the market with the same knowledge, expertise or product offering around hub and spoke. "While the company is still in its infancy, it is growing rapidly, and I am looking forward to working with the team to further strengthen and grow the business to support those working in pharmacy."

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

In a mutual agreement with the STADA board, Roger Scarlett-Smith has stepped down from his role as head of UK. The company has assigned the responsibility of UK operation to Rudolf Bär with current responsibilities as cluster head for Mid-Sized European Markets. Scarlett-Smith joined STADA in October 2018 to lead the UK operation upon the retirement of Dieno George. Prior to this, he had enjoyed an illustrious career in the Consumer Healthcare sector, largely with GlaxoSmithKline, for which he held positions including as President North America, President EMEA and Head of Global Categories. Under his leadership, the STADA UK business has grown sales by 50 per cent and profitability has more than doubled. He has reshaped the business to improve efficiency. There has been a marked acceleration of product innovation including key line extensions to the Zoflora disinfectant range as well as the introduction of a salmeterol and fluticasone inhaler in the Rx respiratory sector. Meanwhile, T+R has developed a fine reputation regionally, being voted number 1 regional company last year and winning many national industry awards.

Ceuta Group has appointed Michael Yates as chief operating officer (COO). In his new role, he will focus on the exploration of future acquisitions to support the Group's growth plans and ensure it continues to provide innovative services and unlock new opportunities for its clients. Prior to joining Ceuta Group, Yates was associated with Procter & Gamble (P&G) for more than 25 years. His career started in the UK and progressed through senior commercial and managing director roles across Europe, Africa and Asia. During his time at P&G, Yates gained insight and experience in building brands in the UK and globally. He has broad category experience across food & drink as well as health, wellness and personal care, having worked with brands such as Pringles, Sunny Delight, Oral B, Vicks, Head & Shoulders and Pantene. With extensive international experience, Michael brings client-side knowledge and insight of successfully expanding brands and adapting business models for markets across the globe. His appointment bolsters Ceuta Group's leadership structure and will support the Group's growth plans and delivery of superior client service.

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

Walgreens Boots Alliance (WBA) has officially announced that Sebastian James, the Managing Director of Boots, will be stepping down from his role to pursue a new opportunity in the healthcare sector. James has given notice to leave the company and will remain with Boots until November. The UK pharmacy giant has already begun the search for a new Managing Director. James is set to take on the role of CEO at Veonet, a leading European chain of ophthalmology clinics. During his tenure as Managing Director since 2018, James played a pivotal role in transforming Boots into the UK's leading health and beauty retailer. He oversaw significant growth and innovation, achieving thirteen consecutive quarters of retail market share growth. Most recently, the company announced strong Q3 results in June with growth across all categories.

Bas Vorsteveld, former Haleon's vice-president and general manager for Great Britain and Ireland (GBI), has been appointed as Kenvue's new area managing director for Northern Europe. In his new role, he will oversee the company's operations across the UK, Ireland, Norway, Sweden, Denmark, and Finland, managing a portfolio of iconic brands, including Nicorette, Aveeno, Johnson's Baby, Listerine, Neutrogena, Calpol, OGX, and Imodium. Vorsteveld has over 30 years of experience in consumer goods and healthcare. At Haleon, he played a pivotal role in driving its GBI business following its separation from GSK, delivering significant growth and earning notable recognition, including Best Company at the UK Pharmacy Awards 2024. He announced his departure from Haleon in October 2024, after "a journey of nearly 19 amazing years." Until recently, Vorsteveld was president of the board of the PAGB, spearheading the organisation's five-year strategy focused on advancing self-care to help alleviate healthcare pressures.